Pharvaris (NASDAQ:PHVS - Free Report) had its price objective hoisted by JMP Securities from $46.00 to $55.00 in a report issued on Friday,Benzinga reports. JMP Securities currently has a market outperform rating on the stock.
Pharvaris Stock Performance
Shares of PHVS traded down $0.13 during mid-day trading on Friday, reaching $17.60. The company's stock had a trading volume of 50,712 shares, compared to its average volume of 51,565. Pharvaris has a 1-year low of $15.21 and a 1-year high of $33.00. The business has a 50-day simple moving average of $19.02 and a two-hundred day simple moving average of $19.36.
Hedge Funds Weigh In On Pharvaris
Large investors have recently modified their holdings of the stock. Public Employees Retirement System of Ohio acquired a new position in Pharvaris in the 3rd quarter valued at about $57,000. Barclays PLC bought a new stake in shares of Pharvaris during the third quarter worth approximately $106,000. Palumbo Wealth Management LLC acquired a new position in shares of Pharvaris in the fourth quarter valued at approximately $196,000. HighVista Strategies LLC increased its stake in shares of Pharvaris by 35.9% during the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company's stock worth $422,000 after purchasing an additional 6,018 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Pharvaris during the 3rd quarter worth approximately $526,000.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
See Also
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
